Annexon (NASDAQ:ANNX) Earns “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Annexon (NASDAQ:ANNX) in a report issued on Friday morning,Benzinga reports.

Several other equities research analysts have also recently commented on ANNX. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Annexon in a report on Friday. Needham & Company LLC reissued a “buy” rating and set a $16.00 target price on shares of Annexon in a report on Friday. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $15.80.

Annexon Price Performance

Shares of NASDAQ:ANNX opened at $5.46 on Friday. Annexon has a 12 month low of $2.27 and a 12 month high of $8.40. The stock has a market cap of $576.87 million, a price-to-earnings ratio of -5.20 and a beta of 1.23. The stock’s 50 day moving average price is $6.91 and its 200 day moving average price is $5.93.

Insider Buying and Selling at Annexon

In other Annexon news, EVP Ted Yednock sold 5,408 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $7.41, for a total value of $40,073.28. Following the transaction, the executive vice president now owns 71,365 shares of the company’s stock, valued at approximately $528,814.65. This represents a 7.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 20,908 shares of company stock valued at $135,768. Corporate insiders own 12.67% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ANNX. Geode Capital Management LLC grew its holdings in shares of Annexon by 18.3% during the 3rd quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock valued at $12,693,000 after acquiring an additional 331,269 shares in the last quarter. Barclays PLC boosted its holdings in Annexon by 212.0% during the third quarter. Barclays PLC now owns 177,765 shares of the company’s stock valued at $1,052,000 after acquiring an additional 120,789 shares during the period. Wellington Management Group LLP boosted its holdings in Annexon by 36.2% during the third quarter. Wellington Management Group LLP now owns 263,360 shares of the company’s stock valued at $1,559,000 after acquiring an additional 69,941 shares during the period. State Street Corp lifted its stake in shares of Annexon by 116.6% in the third quarter. State Street Corp now owns 3,841,879 shares of the company’s stock valued at $22,744,000 after buying an additional 2,068,294 shares during the period. Finally, Quarry LP bought a new stake in shares of Annexon in the third quarter valued at about $118,000.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.